Reuters

By Liam Mo and Eduardo Baptista

BEIJING (Reuters) - Chinese tech giants Alibaba and Baidu slashed prices on Tuesday of large-language models (LLMs) used to power generative artificial intelligence products, as a price war in the cloud computing sector heats up in China.

Alibaba's cloud unit announced price cuts of up to 97% on a range of its Tongyi Qwen LLMs. Its Qwen-Long model, for instance, will cost only 0.0005 yuan per 1,000 tokens -... (continue reading...)

MOSCOW (Reuters) - Russian Foreign Minister Sergei Lavrov, commenting on the helicopter crash that killed Iranian President Ebrahim Raisi, said on Tuesday that U.S. sanctions had worsened aviation safety.

Iranian media reported that images from the site showed the U.S.-made Bell 212 helicopter on which Raisi was travelling slammed into a mountain peak, although there was no official word on the cause of the crash.

Iran was a major buyer... (continue reading...)

(Reuters) - U.S. index futures were muted on Tuesday, as investors refrained from placing big bets before AI chip leader Nvidia's earnings this week and amid policy caution from Federal Reserve officials ahead of the central bank's meeting minutes.

Rate-setters have offered few clues on the timing for rate cuts this year and several Fed officials on Monday refrained from noting inflation moderating to the 2% target despite recent data pointing to... (continue reading...)

By Liz Lee

BEIJING (Reuters) - Chinese Foreign Minister Wang Yi called Taiwan's newly-inaugurated President Lai Ching-te "disgraceful" on Tuesday, stepping up Beijing's rhetoric just a day after he took office.

China, which claims Taiwan as its own territory, believes Lai to be a "separatist", and has rebuffed his offers of talks.

China's government has generally avoided directly naming Lai since he won election in January,... (continue reading...)

By Maggie Fick and Yadarisa Shabong

(Reuters) - AstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by the expected launch of 20 new medicines and through growth in its cancer, biopharmaceuticals and rare disease portfolio.

The Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier expected to launch at least 15 new medicines between 2023 and 2030.